Robert Root-Bernstein. (2022). Biased, Bitopic, Opioid-Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction. MDPI AG.
Chicago Style (17th ed.) CitationRobert Root-Bernstein. Biased, Bitopic, Opioid-Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction. MDPI AG, 2022.
MLA (9th ed.) CitationRobert Root-Bernstein. Biased, Bitopic, Opioid-Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction. MDPI AG, 2022.
Warning: These citations may not always be 100% accurate.